Clinical trial
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
NCT03165734 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 26, 2017
- Completion date
- October 13, 2028
- Enrollment
- 407 (actual)
- Sites
- 207
Conditions
As the registry lists them; a condition with its own page is linked.
post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis